id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-292733-dya40tln	Lancman, Guido	Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia	2020-10-02		.txt	text/plain	1377	84	51	She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge. She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit. Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation. This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyteand antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation. Here, we report a case of severe COVID-19 virus reactivation following chemotherapy, including rituximab, cytarabine, and dasatinib for B cell acute lymphoblastic leukemia (B-ALL).	./cache/cord-292733-dya40tln.txt	./txt/cord-292733-dya40tln.txt